Medical Marijuana - Cannabidiol – Pipeline Insight, 2021
This report can be delivered to the clients within 3-4 Business Days
DelveInsight’s, “Medical Marijuana - Cannabidiol – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Medical Marijuana - Cannabidiol: Overview
The term medical marijuana refers to using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions. The U.S. Food and Drug Administration (FDA) has not recognized or approved the marijuana plant as medicine. However, the scientific study of the chemicals in marijuana, called cannabinoids, has led to some FDA-approved medications that contain cannabinoid chemicals in pill form. Continued research may lead to the approval of more medications. Since it contains chemicals it may help in treating a wide range of illnesses and symptoms; many people argue that it should be legal for medical purposes. A growing number of states have legalized marijuana for medical use. Medical marijuana is the medical use of Cannabis sativa or Cannabis indica plant to relieve symptoms of, or treat diseases and conditions. The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD. THC can increase appetite and reduce nausea. THC may also decrease pain, inflammation (swelling and redness), and muscle control problems. Unlike THC, CBD is a cannabinoid that does not make people 'high.' These drugs are not popular for recreational use because they are not intoxicating. It may be useful in reducing pain and inflammation, controlling epileptic seizures, and possibly even treating mental illness and addictions. The FDA approved a CBD-based liquid medication called Epidiolex for the treatment of two forms of severe childhood epilepsy, Dravet syndrome and Lennox–Gastaut syndrome.
'Medical Marijuana - Cannabidiol - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Medical Marijuana - Cannabidiol pipeline landscape is provided which includes the disease overview and Medical Marijuana - Cannabidiol treatment guidelines. The assessment part of the report embraces, in depth Medical Marijuana - Cannabidiol commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Medical Marijuana - Cannabidiol collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Medical Marijuana - Cannabidiol report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Medical Marijuana - Cannabidiol Emerging Drugs
Further product details are provided in the report……..
Medical Marijuana - Cannabidiol: Therapeutic Assessment
This segment of the report provides insights about the different Medical Marijuana - Cannabidiol drugs segregated based on following parameters that define the scope of the report, such as:
Medical Marijuana - Cannabidiol: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Medical Marijuana - Cannabidiol therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Medical Marijuana - Cannabidiol drugs.
Medical Marijuana - Cannabidiol Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Medical Marijuana - Cannabidiol – Pipeline Insight, 2021,” report provides comprehensive insights about 25+ companies and 50+ pipeline drugs in Medical Marijuana - Cannabidiol pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Medical Marijuana - Cannabidiol: Overview
The term medical marijuana refers to using the whole, unprocessed marijuana plant or its basic extracts to treat symptoms of illness and other conditions. The U.S. Food and Drug Administration (FDA) has not recognized or approved the marijuana plant as medicine. However, the scientific study of the chemicals in marijuana, called cannabinoids, has led to some FDA-approved medications that contain cannabinoid chemicals in pill form. Continued research may lead to the approval of more medications. Since it contains chemicals it may help in treating a wide range of illnesses and symptoms; many people argue that it should be legal for medical purposes. A growing number of states have legalized marijuana for medical use. Medical marijuana is the medical use of Cannabis sativa or Cannabis indica plant to relieve symptoms of, or treat diseases and conditions. The increasing research on medical marijuana shows its therapeutic value for a range of health conditions, including chronic pain, cancer, arthritis, diabetes, depression, anxiety, and many more. Currently, the two main cannabinoids from the marijuana plant that are of medical interest are THC and CBD. THC can increase appetite and reduce nausea. THC may also decrease pain, inflammation (swelling and redness), and muscle control problems. Unlike THC, CBD is a cannabinoid that does not make people 'high.' These drugs are not popular for recreational use because they are not intoxicating. It may be useful in reducing pain and inflammation, controlling epileptic seizures, and possibly even treating mental illness and addictions. The FDA approved a CBD-based liquid medication called Epidiolex for the treatment of two forms of severe childhood epilepsy, Dravet syndrome and Lennox–Gastaut syndrome.
'Medical Marijuana - Cannabidiol - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Medical Marijuana - Cannabidiol pipeline landscape is provided which includes the disease overview and Medical Marijuana - Cannabidiol treatment guidelines. The assessment part of the report embraces, in depth Medical Marijuana - Cannabidiol commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Medical Marijuana - Cannabidiol collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Medical Marijuana - Cannabidiol R&D. The therapies under development are focused on novel approaches to treat/improve Medical Marijuana - Cannabidiol.
This segment of the Medical Marijuana - Cannabidiol report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Medical Marijuana - Cannabidiol Emerging Drugs
- BX-1: Bionorica SE
- Lenabasum: Corbus Pharmaceuticals
- THX-110: Therapix Biosciences
- Cannabis oil: TO Pharmaceuticals
- VSN16R: Canbex Therapeutics
- INM-755: InMed Pharmaceuticals
Further product details are provided in the report……..
Medical Marijuana - Cannabidiol: Therapeutic Assessment
This segment of the report provides insights about the different Medical Marijuana - Cannabidiol drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Medical Marijuana - Cannabidiol
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Medical Marijuana - Cannabidiol: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Medical Marijuana - Cannabidiol therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Medical Marijuana - Cannabidiol drugs.
Medical Marijuana - Cannabidiol Report Insights
- Medical Marijuana - Cannabidiol Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Medical Marijuana - Cannabidiol drugs?
- How many Medical Marijuana - Cannabidiol drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Medical Marijuana - Cannabidiol?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Medical Marijuana - Cannabidiol therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Medical Marijuana - Cannabidiol and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tetra Bio-Pharma
- Corbus Pharmaceuticals
- Bionorica SE
- e3D Pharma
- TO Pharmaceuticals
- Therapix Biosciences
- ANANDA Scientific
- Daisy Pharma Opioid Venture
- Canbex Therapeutics
- InMed Pharmaceuticals
- Botanix Pharmaceuticals
- Centrexion Therapeutics
- Tilray
- One World Cannabis
- Epm Group
- Zelira Therapeutics
- Pascal Biosciences
- Cannovex
- Can-Fite Pharma
- GB Sciences
- Serina Therapeutics
- Oxford Cannabinoid Technologies
- Cannabis Science
- PPP011
- Lenabasum
- BX-1
- e3D-01
- e3D-03
- Cannabis Oil
- THX-110
- Nantheia A1002N5S
- Dronabinol
- VSN16R
- INM-755
- BTX 1503
- BTX1801
- CNTX-6016
- TN-TC11G
- OWC MGC cream
- BTX1702
- e3D-05
- EPM301
- Research programme: Cancer therapeutics
- Research programme: cannabinoid-based formulations
- PAS-403
- PAS-393
- Pascal Cannabinoid
- Research programme: cannabidiol-combination therapies
- Research programme: cannabidiol therapy
- Research programme: Synthetic CBD analogs
- Supera-CBD
- KLS-13019
- CNX-004
- CNX-005
- CNX-006
- INM-088
- A3AR-based Cannabis Compounds
- EPM302
- EPM305
- EPM306
- Cannabinoid containing complex mixtures (CCCM™)
- Cannabinoid-Based Medical Compound
- SER-228
- OCT461201
- CNX-001
- CNX-002
- CNX-003
- CS-S/BCC-1
Introduction
Executive Summary
Medical Marijuana - Cannabidiol: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
BX-1: Bionorica SE
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
THX-110: Therapix Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
CNTX 6016: Centrexion Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Medical Marijuana - Cannabidiol Key Companies
Medical Marijuana - Cannabidiol Key Products
Medical Marijuana - Cannabidiol- Unmet Needs
Medical Marijuana - Cannabidiol- Market Drivers and Barriers
Medical Marijuana - Cannabidiol- Future Perspectives and Conclusion
Medical Marijuana - Cannabidiol Analyst Views
Medical Marijuana - Cannabidiol Key Companies
Appendix
Executive Summary
Medical Marijuana - Cannabidiol: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
BX-1: Bionorica SE
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Mid Stage Products (Phase II)
Comparative Analysis
THX-110: Therapix Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Early stage products (Phase I/II)
Comparative Analysis
CNTX 6016: Centrexion Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report
Inactive Products
Comparative Analysis
Medical Marijuana - Cannabidiol Key Companies
Medical Marijuana - Cannabidiol Key Products
Medical Marijuana - Cannabidiol- Unmet Needs
Medical Marijuana - Cannabidiol- Market Drivers and Barriers
Medical Marijuana - Cannabidiol- Future Perspectives and Conclusion
Medical Marijuana - Cannabidiol Analyst Views
Medical Marijuana - Cannabidiol Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Medical Marijuana - Cannabidiol
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Medical Marijuana - Cannabidiol
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Medical Marijuana - Cannabidiol
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Medical Marijuana - Cannabidiol
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products